Search Results

Nicolas G. Bazan Invited Lectures on Elovanoids in 2019

 

 

April 3-7, 2019 - DZNE Scientific Symposium and 10 year Celebration of the DZNE, Bonn, Germany

Title of Lecture: "Specific signals that remodel retinal transcriptome for cell survival upon Amyloid-beta peptide oligomer damage: Elovanoids as molecular guardians"

 

April 28- May 2, 2019 – ARVO, Association for Research in Vision and Ophthalmology, Vancouver, BC, Canada

Co-Moderator Session: Lipids in Diverse function and pathologies of the eye – SIG (Special Interest Group).

Title of Lecture: “Elovanoids are mediators of the omega-3 lipidome and target transcriptome architecture to sustain photoreceptor function”

and

Session: Lipids and Eye Diseases – Where should we focus? – SIG (Special Interest Group)

Title of Lecture:  “Elovanoids act as epigenetic regulators in cell survival/senescence decisions in photoreceptors”

 
August 22, 2019 – Unity Biotechnology meeting, San Francisco, CA
Title of Lectures - “Brain resiliency in aging and at the onset of damage and of neurodegenerative diseases”
 
September 20-21, 2019 - VII. International DOG, (Deutsche Ophthalmologische Gesellschaft (German Ophthalmological Society -Symposium on Age-Related Macular Degeneration. Understanding Pathogenic Mechanisms of Disease, Baden-Baden, Germany

Distinguished Lecturer – “Elovanoids are novel photoreceptor survival signals relevant to AMD”

 

September 26, 2019 – Henry Stewart Talks

Title of Talk – Part 1: Photoreceptor protection: Significance of docosanoids and elovanoids

1: Docosahexaenoic acid (DHA) [Video file]. In The Biomedical & Life Sciences Collection. Henry Stewart Talks. Retrieved October 2, 2019, from https//hstalks.com/bs/4033/.

Title of Talk – Part 2: Photoreceptor protection: Significance of docosanoids and elovanoids

2: Bioactive derivatives of DHA [Video file]. In The Biomedical & Life Sciences Collection. Henry Stewart Talks. Retrieved October 2, 2019, from https//hstalks.com/bs/4044/.

 

September 29-October 1, 2019 – The 14th Fatty Acids and Cell Signaling FACS Conference: Fatty Acid Metabolism and Oxidation, Austin, TX

Keynote Lecture – “Elovanoid bioactivity: Significance to Alzheimer’s, traumatic brain injury and Age-related macular degeneration”

 

 

October 19-23, 2019 – Society for Neuroscience, Chicago, IL

Oral Presentation: Nanosymposium

Title of Lecture – “The Novel class of homeostatic lipid mediators, elovanoids, provide high-grade neuroprotection in experimental traumatic brain injury”

Abstract Control No.:  3431
Session Title: Traumatic Brain Injury
Location: McCormick Place, Room S404
Session Number:  541
Session Time:  10/22/2019 1:00:00 PM- 10/22/2019 4:15:00 PM

Presentation Number:  541.11
Presentation Time:  10/22/2019 3:30:00 PM- 10/22/2019 3:45:00 PM

*L. S. BELAYEV1, A. OBENAUS2, E. HADDAD2, L. KHOUTOROVA1, V. A. CRUZ FLORES3, P. MUKHERJEE1, N. A. PETASIS4, N. BAZAN1;


October 20-23, 2019 – 16th International Conference on Bioactive Lipids in Cancer, Inflammation and Related Diseases, St. Peterburg, FL

Co-Moderator Session 3: Neuronal Inflammation

Title of Lecture – “Elovanoids counteract oligomeric b-amyloid toxicity, regulate transcriptome architecture and function: Significance to Alzheimer’s and Age-related macular degeneration”

 
 
 

 

Nicolas G. Bazan Invited Lectures on Elovanoids in 2020

 
February 27-29, 2020 – 15th Annual Conference on Brain Injury, “Best Practices in Brain Injury Medicine and Neurorehabilitation: Improving Outcomes through Interdisciplinary Collaboration, New Orleans, LA
Title of Lecture – “Elovanoids are neuroprotective in an experimental model of traumatic brain injury”

Abstract #63

 

February 27-29, 2020 – 15th Annual Conference on Brain Injury, “Best Practices in Brain Injury Medicine and Neurorehabilitation: Improving Outcomes through Interdisciplinary Collaboration, New Orleans, LA
Ludmila Belayev - Intranasal delivery of elovanoids, novel class of homeostatic lipid mediators, improves neurobehavioral functions and confers neuroprotection on rats with traumatic brain injury

Abstract #64

 

February 27-29, 2020 – 15th Annual Conference on Brain Injury, “Best Practices in Brain Injury Medicine and Neurorehabilitation: Improving Outcomes through Interdisciplinary Collaboration, New Orleans, LA
Surjyadipta Bhattacharjee - Elovanoids (ELV) protect telomere length shortening and restore of Telomerase activity upon exposure to uncompensated oxidative stress (UOS) or oligomeric amyloid β (Oaβ) recapitulating brain injury.

Abstract #115

 

February 27-29, 2020 – 15th Annual Conference on Brain Injury, “Best Practices in Brain Injury Medicine and Neurorehabilitation: Improving Outcomes through Interdisciplinary Collaboration, New Orleans, LA
Alexander Ledet - Elovanoids reduce microtubule-associated protein tau (MAPT) missorting.

Abstract #119

 

March 26, 2020 – Frontiers in Vision Research Lecture Series, Bascon Palmer Eye Institute, University of Miami Health System, Miami, FL
Title of Lecture – “Elovanoids: are molecular guardians of photoreceptor cell integrity: Significance for retinal degenerative diseases”

 

April 23, 2020 – Schepens/Mass Eye and Ear Institute Distinguished lecture, Harvard University, Boston, MA
Title of Lecture – “Elovanoids modulate the transcriptome of the retina: Significance for retinal degeneration”

Nicolas G. Bazan Invited Lectures on Elovanoids in 2019

April 3-7, 2019 - DZNE Scientific Symposium and 10 year Celebration of the DZNE, Bonn, Germany

Title of Lecture: "Specific signals that remodel retinal transcriptome for cell survival upon Amyloid-beta peptide oligomer damage: Elovanoids as molecular guardians"

 

April 28- May 2, 2019 – ARVO, Association for Research in Vision and Ophthalmology, Vancouver, BC, Canada

Co-Moderator Session: Lipids in Diverse function and pathologies of the eye – SIG (Special Interest Group).

Title of Lecture: “Elovanoids are mediators of the omega-3 lipidome and target transcriptome architecture to sustain photoreceptor function”

and

Session: Lipids and Eye Diseases – Where should we focus? – SIG (Special Interest Group)

Title of Lecture:  “Elovanoids act as epigenetic regulators in cell survival/senescence decisions in photoreceptors”

 
August 22, 2019 – Unity Biotechnology meeting, San Francisco, CA
Title of Lectures - “Brain resiliency in aging and at the onset of damage and of neurodegenerative diseases”
 
September 20-21, 2019 - VII. International DOG, (Deutsche Ophthalmologische Gesellschaft (German Ophthalmological Society -Symposium on Age-Related Macular Degeneration. Understanding Pathogenic Mechanisms of Disease, Baden-Baden, Germany

Distinguished Lecturer – “Elovanoids are novel photoreceptor survival signals relevant to AMD”

 

September 26, 2019 – Henry Stewart Talks

Title of Talk – Part 1: Photoreceptor protection: Significance of docosanoids and elovanoids

1: Docosahexaenoic acid (DHA) [Video file]. In The Biomedical & Life Sciences Collection. Henry Stewart Talks. Retrieved October 2, 2019, from https//hstalks.com/bs/4033/.

Title of Talk – Part 2: Photoreceptor protection: Significance of docosanoids and elovanoids

2: Bioactive derivatives of DHA [Video file]. In The Biomedical & Life Sciences Collection. Henry Stewart Talks. Retrieved October 2, 2019, from https//hstalks.com/bs/4044/.

 

September 29-October 1, 2019 – The 14th Fatty Acids and Cell Signaling FACS Conference: Fatty Acid Metabolism and Oxidation, Austin, TX

Keynote Lecture – “Elovanoid bioactivity: Significance to Alzheimer’s, traumatic brain injury and Age-related macular degeneration”

 

 

October 19-23, 2019 – Society for Neuroscience, Chicago, IL

Oral Presentation: Nanosymposium

Title of Lecture – “The Novel class of homeostatic lipid mediators, elovanoids, provide high-grade neuroprotection in experimental traumatic brain injury”

Abstract Control No.:  3431
Session Title: Traumatic Brain Injury
Location: McCormick Place, Room S404
Session Number:  541
Session Time:  10/22/2019 1:00:00 PM- 10/22/2019 4:15:00 PM

Presentation Number:  541.11
Presentation Time:  10/22/2019 3:30:00 PM- 10/22/2019 3:45:00 PM

*L. S. BELAYEV1, A. OBENAUS2, E. HADDAD2, L. KHOUTOROVA1, V. A. CRUZ FLORES3, P. MUKHERJEE1, N. A. PETASIS4, N. BAZAN1;


October 20-23, 2019 – 16th International Conference on Bioactive Lipids in Cancer, Inflammation and Related Diseases, St. Peterburg, FL

Co-Moderator Session 3: Neuronal Inflammation

Title of Lecture – “Elovanoids counteract oligomeric b-amyloid toxicity, regulate transcriptome architecture and function: Significance to Alzheimer’s and Age-related macular degeneration”

 
 
 

 

Nicolas G. Bazan Invited Lectures on Elovanoids in 2020

 
February 27-29, 2020 – 15th Annual Conference on Brain Injury, “Best Practices in Brain Injury Medicine and Neurorehabilitation: Improving Outcomes through Interdisciplinary Collaboration, New Orleans, LA
Title of Lecture – “Elovanoids are neuroprotective in an experimental model of traumatic brain injury”

Abstract #63

 

February 27-29, 2020 – 15th Annual Conference on Brain Injury, “Best Practices in Brain Injury Medicine and Neurorehabilitation: Improving Outcomes through Interdisciplinary Collaboration, New Orleans, LA
Ludmila Belayev - Intranasal delivery of elovanoids, novel class of homeostatic lipid mediators, improves neurobehavioral functions and confers neuroprotection on rats with traumatic brain injury

Abstract #64

 

February 27-29, 2020 – 15th Annual Conference on Brain Injury, “Best Practices in Brain Injury Medicine and Neurorehabilitation: Improving Outcomes through Interdisciplinary Collaboration, New Orleans, LA
Surjyadipta Bhattacharjee - Elovanoids (ELV) protect telomere length shortening and restore of Telomerase activity upon exposure to uncompensated oxidative stress (UOS) or oligomeric amyloid β (Oaβ) recapitulating brain injury.

Abstract #115

 

February 27-29, 2020 – 15th Annual Conference on Brain Injury, “Best Practices in Brain Injury Medicine and Neurorehabilitation: Improving Outcomes through Interdisciplinary Collaboration, New Orleans, LA
Alexander Ledet - Elovanoids reduce microtubule-associated protein tau (MAPT) missorting.

Abstract #119

 

March 26, 2020 – Frontiers in Vision Research Lecture Series, Bascon Palmer Eye Institute, University of Miami Health System, Miami, FL
Title of Lecture – “Elovanoids: are molecular guardians of photoreceptor cell integrity: Significance for retinal degenerative diseases”

 

April 23, 2020 – Schepens/Mass Eye and Ear Institute Distinguished lecture, Harvard University, Boston, MA
Title of Lecture – “Elovanoids modulate the transcriptome of the retina: Significance for retinal degeneration”

Nicolas G. Bazan Invited Lectures on Elovanoids in 2019

April 3-7, 2019 - DZNE Scientific Symposium and 10 year Celebration of the DZNE, Bonn, Germany

Title of Lecture: "Specific signals that remodel retinal transcriptome for cell survival upon Amyloid-beta peptide oligomer damage: Elovanoids as molecular guardians"

 

April 28- May 2, 2019 – ARVO, Association for Research in Vision and Ophthalmology, Vancouver, BC, Canada

Co-Moderator Session: Lipids in Diverse function and pathologies of the eye – SIG (Special Interest Group).

Title of Lecture: “Elovanoids are mediators of the omega-3 lipidome and target transcriptome architecture to sustain photoreceptor function”

and

Session: Lipids and Eye Diseases – Where should we focus? – SIG (Special Interest Group)

Title of Lecture:  “Elovanoids act as epigenetic regulators in cell survival/senescence decisions in photoreceptors”

 
August 22, 2019 – Unity Biotechnology meeting, San Francisco, CA
Title of Lectures - “Brain resiliency in aging and at the onset of damage and of neurodegenerative diseases”
 
September 20-21, 2019 - VII. International DOG, (Deutsche Ophthalmologische Gesellschaft (German Ophthalmological Society -Symposium on Age-Related Macular Degeneration. Understanding Pathogenic Mechanisms of Disease, Baden-Baden, Germany

Distinguished Lecturer – “Elovanoids are novel photoreceptor survival signals relevant to AMD”

 

September 26, 2019 – Henry Stewart Talks

Title of Talk – Part 1: Photoreceptor protection: Significance of docosanoids and elovanoids

1: Docosahexaenoic acid (DHA) [Video file]. In The Biomedical & Life Sciences Collection. Henry Stewart Talks. Retrieved October 2, 2019, from https//hstalks.com/bs/4033/.

Title of Talk – Part 2: Photoreceptor protection: Significance of docosanoids and elovanoids

2: Bioactive derivatives of DHA [Video file]. In The Biomedical & Life Sciences Collection. Henry Stewart Talks. Retrieved October 2, 2019, from https//hstalks.com/bs/4044/.

 

September 29-October 1, 2019 – The 14th Fatty Acids and Cell Signaling FACS Conference: Fatty Acid Metabolism and Oxidation, Austin, TX

Keynote Lecture – “Elovanoid bioactivity: Significance to Alzheimer’s, traumatic brain injury and Age-related macular degeneration”

 

 

October 19-23, 2019 – Society for Neuroscience, Chicago, IL

Oral Presentation: Nanosymposium

Title of Lecture – “The Novel class of homeostatic lipid mediators, elovanoids, provide high-grade neuroprotection in experimental traumatic brain injury”

Abstract Control No.:  3431
Session Title: Traumatic Brain Injury
Location: McCormick Place, Room S404
Session Number:  541
Session Time:  10/22/2019 1:00:00 PM- 10/22/2019 4:15:00 PM

Presentation Number:  541.11
Presentation Time:  10/22/2019 3:30:00 PM- 10/22/2019 3:45:00 PM

*L. S. BELAYEV1, A. OBENAUS2, E. HADDAD2, L. KHOUTOROVA1, V. A. CRUZ FLORES3, P. MUKHERJEE1, N. A. PETASIS4, N. BAZAN1;


October 20-23, 2019 – 16th International Conference on Bioactive Lipids in Cancer, Inflammation and Related Diseases, St. Peterburg, FL

Co-Moderator Session 3: Neuronal Inflammation

Title of Lecture – “Elovanoids counteract oligomeric b-amyloid toxicity, regulate transcriptome architecture and function: Significance to Alzheimer’s and Age-related macular degeneration”

 
 
 

 

Nicolas G. Bazan Invited Lectures on Elovanoids in 2020

 
February 27-29, 2020 – 15th Annual Conference on Brain Injury, “Best Practices in Brain Injury Medicine and Neurorehabilitation: Improving Outcomes through Interdisciplinary Collaboration, New Orleans, LA
Title of Lecture – “Elovanoids are neuroprotective in an experimental model of traumatic brain injury”

Abstract #63

 

February 27-29, 2020 – 15th Annual Conference on Brain Injury, “Best Practices in Brain Injury Medicine and Neurorehabilitation: Improving Outcomes through Interdisciplinary Collaboration, New Orleans, LA
Ludmila Belayev - Intranasal delivery of elovanoids, novel class of homeostatic lipid mediators, improves neurobehavioral functions and confers neuroprotection on rats with traumatic brain injury

Abstract #64

 

February 27-29, 2020 – 15th Annual Conference on Brain Injury, “Best Practices in Brain Injury Medicine and Neurorehabilitation: Improving Outcomes through Interdisciplinary Collaboration, New Orleans, LA
Surjyadipta Bhattacharjee - Elovanoids (ELV) protect telomere length shortening and restore of Telomerase activity upon exposure to uncompensated oxidative stress (UOS) or oligomeric amyloid β (Oaβ) recapitulating brain injury.

Abstract #115

 

February 27-29, 2020 – 15th Annual Conference on Brain Injury, “Best Practices in Brain Injury Medicine and Neurorehabilitation: Improving Outcomes through Interdisciplinary Collaboration, New Orleans, LA
Alexander Ledet - Elovanoids reduce microtubule-associated protein tau (MAPT) missorting.

Abstract #119

 

March 26, 2020 – Frontiers in Vision Research Lecture Series, Bascon Palmer Eye Institute, University of Miami Health System, Miami, FL
Title of Lecture – “Elovanoids: are molecular guardians of photoreceptor cell integrity: Significance for retinal degenerative diseases”

 

April 23, 2020 – Schepens/Mass Eye and Ear Institute Distinguished lecture, Harvard University, Boston, MA
Title of Lecture – “Elovanoids modulate the transcriptome of the retina: Significance for retinal degeneration”

  • Home
  • Clinical Need
  • Technology
  • Team
  • News
  • Contact

NeuResto Therapeutics 

NeuResto Therapeutics was founded to pursue novel approaches to neuroprotection for ischemic stroke and wet AMD and neurorestoration for diseases such as TBI/concussion.

Nicolas G. Bazan, M.D., Ph.D. | Co-founder, President & CEO

  • Dr. Bazan is the Director of Neuroscience at the Louisiana State University Health Sciences Center, where he oversees over 90 researchers. 
  • Expert in experimental models of stroke and traumatic brain injury, with over 35 years of continuous NIH funding. 
  • Decades of experience in pharmaceutical development regarding eye and brain medications. 

Nicos Petasis, Ph.D. | Co-founder, Chief Scientific Officer

  • Dr. Petasis is a faculty member and Professor of Chemistry and Pharmacology in the University of Southern California's Department of Chemistry. 
  • Decades of experience in pharmaceutical development regarding the chemical processes of cancer and other medications.  

Founders & Leadership Team

Scientific Advisory Board

John E. Dowling, Ph.D.

  • Dr. Dowling is a Professor Emeritus at Harvard University, a member of the National Academy of Sciences, and a fellow of the American Academy of Arts and Sciences
  • Contributed to our understanding of the functional organization of the retina, its synaptic organization, the electrical responses of the retinal neurons, and the mechanisms underlying neurotransmission and neuromodulation in the retina.

Edmond H. Fischer, Ph.D.

  • Dr. Fischer is the 1992 Nobel Prize in Physiology or Medicine co-recipient for describing how reversible phosphorylation works as a switch to activate proteins and regulate various cellular processes.
  • Professor Emeritus of biochemistry at the University of Washington.

Bengt I. Samuelsson, Ph.D.

  • Dr. Samuelsson is the 1982 Nobel Prize for Physiology or Medicine co-recipient for discoveries concerning prostaglandins and related substances.
  • Served on the board of directors of Pharmacia AB, NicOx S.A. and Schering AG and is an advisor to the venture capital fund HealthCap.

Pierluigi Nicotera, Ph.D.

  • Dr. Nicotera is the Scientific Director and Chairman of the Executive Board of the German Center for Neurodegenerative Diseases  and has been a member of the German Academy of Science since 2016.
  • Has presented his discoveries on ‘Molecular switches in neuronal cell death’ (Lecture at the 37th Nobel Conference on Apoptosis, Stockholm, 2002) and on ‘Synaptic damage in neurodegeneration’ (Lecture at the Nobel Conference on Cell Cycle and Apoptosis. 200-year Anniversary of the Karolinska Institute. Stockholm, Sweden, 2010).

Hernan A. Bazan, M.D., DFSVS, FACS | Co-founder, Chief Medical Officer

  • Dr. Bazan is an academic vascular surgeon specializing in acute stroke treatment.
  • CEO & Co-founder of South Rampart Pharma, LLC.